Dual-Responsive Nanodelivery System Synergizes Elevation in Hypoxia with PD-L1 Blocking to Activate Systemic Immunity and Inhibit Distant Tumors.

The hypoxia of the tumor microenvironment is insufficient to fully activate the efficacy of hypoxia-activated prodrugs (HAPs), while severe hypoxia elevates the expression of the hypoxia-inducible factor (HIF-1α), leading to tumor metastasis and immune evasion. This study has constructed a nanomicelle (HACA/GOx@AF/TPZ) that is composed of a coassembly of hyaluronic acid-cinnamaldehyde Schiff base (HACA), glucose oxidase (GOx), tirapazamine (TPZ), and acriflavine (AF). HACA/GOx@AF/TPZ releases the drugs it carries within the tumor microenvironment: the catalytic oxidation of glucose by GOx eliminates oxygen within the tumor, further activating TPZ and generating cytotoxic free radicals to kill the tumor cells. Meanwhile, AF can specifically inhibit HIF-1α through a multistage response, downregulating the expression of VEGF and facilitating the conversion of the tumor microenvironment (TME) to an antitumor TME, inducing dendritic cell maturation and polarization of M2 macrophages to M1. The "hypoxia-activated immune modulation" combination therapy strategy using HACA/GOx@AF/TPZ may provide more possibilities for combined tumor treatment.

• Publication year

  2025

• Venue

  ACS Applied Materials and Interfaces

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1021/acsami.5c17647PMID 41211720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucose oxidase/copper‑carbon dots/hyaluronic acid self-assembly for self-supply hydrogen peroxide in a double-enzyme cascade to enhance anti-tumor therapy.

  2025cited by this paper
• Hypoxia-Targeted-Therapy: Mussel-inspired hollow polydopamine nanocarrier containing MoS2 nanozyme and tirapazamine with anti-angiogenesis property for synergistic tumor therapy.

  2025cited by this paper
• pH-Responsive Hyaluronic Acid Nanomicelles for Photodynamic /Chemodynamic Synergistic Therapy Trigger Immunogenicity and Oxygenation.

  2024cited by this paper
• Iron-based MOF with Catalase-like activity improves the synergistic therapeutic effect of PDT/ferroptosis/starvation therapy by reversing the tumor hypoxic microenvironment

  2024cited by this paper
• A Glucose Oxidase-Curcumin Composite Nanoreactor for Multimodal Synergistic Cancer Therapy.

  2024cited by this paper
• Immunoantitumor Activity and Oxygenation Effect Based on Iron-Copper-Doped Folic Acid Carbon Dots.

  2024cited by this paper
• Multifunctional manganese oxide-based nanocomposite theranostic agent with glucose/light-responsive singlet oxygen generation and dual-modal imaging for cancer treatment.

  2023cited by this paper
• Targeting intratumoral hypoxia to enhance anti-tumor immunity.

  2023cited by this paper
• Macrophages in immunoregulation and therapeutics

  2023cited by this paper
• Advances in Immunogenic Cell Death for Cancer Immunotherapy

  2023cited by this paper
• Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions

  2023cited by this paper
• Autocatalytic oncotherapy nanosystem with glucose depletion for the cascade amplification of hypoxia-activated chemotherapy and H2O2-dependent chemodynamic therapy.

  2022cited by this paper
• IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein.

  2022cited by this paper
• Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art

  2022cited by this paper
• Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

  2022cited by this paper
• Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy

  2021cited by this paper
• MnO2-Based Nanomotors with Active Fenton-like Mn2+ Delivery for Enhanced Chemodynamic Therapy.

  2021cited by this paper
• Biomimetic Nanoreactor for Cancer Eradication via Win-Win Cooperation between Starvation/Photo/Chemodynamic Therapies.

  2021cited by this paper
• Synthesis, spectroscopic characterization and biological applications of some novel Schiff base transition metal (II) complexes derived from curcumin moiety

  2021cited by this paper
• Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy

  2021cited by this paper
• A Glucose/Oxygen-Exhausting Nanoreactor for Starvation- and Hypoxia-Activated Sustainable and Cascade Chemo-Chemodynamic Therapy.

  2020cited by this paper
• Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using HIF-1 Inhibitor.

  2020cited by this paper
• Administration of fusion cytokines induces tumor regression and systemic antitumor immunity

  2020cited by this paper
• Self-accelerating H2O2-responsive Plasmonic Nanovesicles for Synergistic Chemo/starving therapy of Tumors

  2020cited by this paper
• Detection of immunogenic cell death and its relevance for cancer therapy

  2020cited by this paper
• Recent Advances in Glucose-Oxidase-Based Nanocomposites for Tumor Therapy.

  2019cited by this paper
• Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis

  2019cited by this paper
• Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses

  2019cited by this paper
• Erythrocyte Membrane Cloaked Metal-Organic Framework Nanoparticle as Biomimetic Nanoreactor for Starvation-Activated Colon Cancer Therapy.

  2018cited by this paper
• Exosomes From Adipose-Derived Stem Cells Attenuate Adipose Inflammation and Obesity Through Polarizing M2 Macrophages and Beiging in White Adipose Tissue

  2017cited by this paper
• Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

  2016cited by this paper
• The synergistic radiosensitizing effect of tirapazamine-conjugated gold nanoparticles on human hepatoma HepG2 cells under X-ray irradiation

  2016cited by this paper
• Inhibition of hypoxia-inducible factor 1 with acriflavine sensitizes hypoxic tumor cells to photodynamic therapy with zinc phthalocyanine-encapsulating cationic liposomes

  2016cited by this paper
• Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs

  2016cited by this paper
• Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine*

  2015cited by this paper
• PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

  2014cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Molecular aspects of tumour hypoxia

  2008cited by this paper
• Calreticulin exposure dictates the immunogenicity of cancer cell death

  2007cited by this paper
• High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

  2005cited by this paper
• Function of CD80 and CD86 on monocyte- and stem cell-derived dendritic cells.

  2003cited by this paper
• Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

  2001cited by this paper
• Metabolism of tirapazamine by multiple reductases in the nucleus.

  2001cited by this paper
• FTIR Study on Molecular Motions of Benzene Adsorbed in ZSM-5 Zeolite: Role of Charge-Balancing Cations and Pore Size

  2001cited by this paper
• Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.

  1999cited by this paper
• Dynamic and structural properties of glucose oxidase enzyme

  1998cited by this paper

• Nanoengineered Light-Switchable Micelles for Dual Chemo-Photodynamic Immunotherapy in Esophageal Cancer via Spatiotemporal Control of the Tumor Microenvironment.

  2025cites this paper